FGF23 beyond Phosphotropic Hormone

Trends in Endocrinology and Metabolism

Volumn 29, Issue 11, 2018, Pages 755-767

  Takashi, Yuichi ^a   Fukumoto, Seiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

chronic kidney disease; fibroblast growth factor 23; fibroblast growth factor receptor; phosphate; Klotho

Indexed keywords

ALDOSTERONE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; HORMONE; KLOTHO PROTEIN; PHOSPHATE; VITAMIN D;

ANEMIA; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYPERTENSION; IMMUNITY; INFLAMMATION; IRON METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM;

ANIMALS; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HORMONES; HUMANS; PHOSPHATES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 85053029623     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2018.08.006     Document Type: Review

References (117)

1. Fukumoto, S., Martin, T.J., Bone as an endocrine organ. Trends Endocrinol. Metab. 20 (2009), 230–236.
2. ADHR Consortium, Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000), 345–348.
3. Yamashita, T., et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000), 494–498.
4. Shimada, T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 6500–6505.
5. Shimada, T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004), 429–435.
6. Shimada, T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004), 561–568.
7. Hori, M., et al. Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152 (2011), 4–10.
8. Itoh, N., Ornitz, D.M., Evolution of the Fgf and Fgfr gene families. Trends Genet. 20 (2004), 563–569.
9. Ornitz, D.M., Itoh, N., The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4 (2015), 215–266.
10. Feng, J.Q., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006), 1310–1315.
11. Liu, S., et al. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291 (2006), E38–E49.
12. Ben-Dov, I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117 (2007), 4003–4008.
13. Olauson, H., et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet., 9, 2013, e1003975.
14. Kawakami, K., et al. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci. Rep., 7, 2017, 40534.
15. Quarles, L.D., Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp. Cell Res. 318 (2012), 1040–1048.
16. Ferrari, S.L., et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90 (2005), 1519–1524.
17. Perwad, F., et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146 (2005), 5358–5364.
18. Hori, M., et al. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J. Bone Miner. Metab. 34 (2016), 132–139.
19. Kurosu, H., et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281 (2006), 6120–6123.
20. Urakawa, I., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
21. Fukumoto, S., Yamashita, T., FGF23 is a hormone-regulating phosphate metabolism – unique biological characteristics of FGF23. Bone 40 (2007), 1190–1195.
22. Yamazaki, Y., et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 23 (2008), 1509–1518.
23. Frishberg, Y., et al. Hyperostosis–hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 22 (2007), 235–242.
24. Tagliabracci, V.S., et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5520–5525.
25. Kuro-o, M., et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
26. Chen, G., et al. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553 (2018), 461–466.
27. Goetz, R., Mohammadi, M., Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14 (2013), 166–180.
28. Gotoh, N., Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 99 (2008), 1319–1325.
29. Andrukhova, O., et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 33 (2014), 229–246.
30. Andrukhova, O., et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6 (2014), 744–759.
31. Smith, R.C., et al. Circulating αKlotho influences phosphate handling by controlling FGF23 production. J. Clin. Invest. 122 (2012), 4710–4715.
32. Moe, S., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69 (2006), 1945–1953.
33. Weber, T.J., et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18 (2003), 1227–1234.
34. Isakova, T., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79 (2011), 1370–1378.
35. Gutierrez, O.M., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359 (2008), 584–592.
36. Fukumoto, S., Shimizu, Y., Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J. Bone Miner. Metab. 29 (2011), 507–514.
37. Fukumoto, S., FGF23–FGF receptor/Klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif. Tissue Int. 98 (2016), 334–340.
38. Fukumoto, S., Targeting fibroblast growth factor 23 signaling with antibodies and inhibitors, is there a rationale?. Front. Endocrinol. (Lausanne), 9, 2018, 48.
39. Carpenter, T.O., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 124 (2014), 1587–1597.
40. Imel, E.A., et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J. Clin. Endocrinol. Metab. 100 (2015), 2565–2573.
41. Carpenter, T.O., et al. Burosumab therapy in children with X-linked hypophosphatemia. N. Engl. J. Med. 378 (2018), 1987–1998.
42. Hasegawa, H., et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78 (2010), 975–980.
43. Shalhoub, V., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122 (2012), 2543–2553.
44. Zoccali, C., et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J. Am. Soc. Nephrol. 15 (2004), 1029–1037.
45. Faul, C., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121 (2011), 4393–4408.
46. Grabner, A., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22 (2015), 1020–1032.
47. Faul, C., Fibroblast growth factor 23 and the heart. Curr. Opin. Nephrol. Hypertens. 21 (2012), 369–375.
48. Leifheit-Nestler, M., et al. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Nephrol. Dial. Transplant. 32 (2017), 1493–1503.
49. Leifheit-Nestler, M., et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transplant. 31 (2016), 1088–1099.
50. Grabner, A., et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci. Rep., 7, 2017, 1993.
51. Isakova, T., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
52. Mirza, M.A., et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207 (2009), 546–551.
53. Jovanovich, A., et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231 (2013), 114–119.
54. Takashi, Y., et al. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. Endocr. Res. 42 (2017), 132–137.
55. Liu, E.S., et al. Increased circulating FGF23 does not lead to cardiac hypertrophy in the male Hyp mouse model of XLH. Endocrinology 159 (2018), 2165–2172.
56. Marthi, A., et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J. Am. Soc. Nephrol. 29 (2018), 2015–2027.
57. London, G.M., et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18 (2003), 1731–1740.
58. Li, X., et al. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ. Res. 98 (2006), 905–912.
59. Villa-Bellosta, R., et al. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 1030–1036.
60. Balci, M., et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial. Int. 14 (2010), 425–432.
61. Nasrallah, M.M., et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 25 (2010), 2679–2685.
62. Jimbo, R., et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85 (2014), 1103–1111.
63. Richter, B., et al. Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch. 468 (2016), 1621–1635.
64. Stevens, K.K., et al. Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int. J. Nephrol., 2011, 2011, 297070.
65. Shimada, T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004), 409–414.
66. Scialla, J.J., et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83 (2013), 1159–1168.
67. Dalrymple, L.S., Go, A.S., Epidemiology of acute infections among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3 (2008), 1487–1493.
68. Thompson, S., et al. Cause of death in patients with reduced kidney function. J. Am. Soc. Nephrol. 26 (2015), 2504–2511.
69. Chonchol, M., et al. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J. Am. Soc. Nephrol. 27 (2016), 227–237.
70. Rossaint, J., et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J. Clin. Invest. 126 (2016), 962–974.
71. 2 D in macrophages. FEBS Lett. 590 (2016), 53–67.
72. Masuda, Y., et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol. Pharm. Bull. 38 (2015), 687–693.
73. Zasloff, M., Fighting infections with vitamin D. Nat. Med. 12 (2006), 388–390.
74. Bacchetta, J., et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J. Bone Miner. Res. 28 (2013), 46–55.
75. Kimmel, P.L., et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54 (1998), 236–244.
76. Barreto, D.V., et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 77 (2010), 550–556.
77. Singh, S., et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90 (2016), 985–996.
78. Fon Tacer, K., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24 (2010), 2050–2064.
79. Ito, N., et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol. Cell. Endocrinol. 399 (2015), 208–218.
80. David, V., et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89 (2016), 135–146.
81. Imel, E.A., et al. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J. Bone Miner. Res. 22 (2007), 520–526.
82. White, K.E., et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60 (2001), 2079–2086.
83. Shimada, T., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 (2002), 3179–3182.
84. Imel, E.A., et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 96 (2011), 3541–3549.
85. Farrow, E.G., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), E1146–E1155.
86. Clinkenbeard, E.L., et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J. Bone Miner. Res. 29 (2014), 361–369.
87. Shimizu, Y., et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45 (2009), 814–816.
88. Schouten, B.J., et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J. Clin. Endocrinol. Metab. 94 (2009), 2332–2337.
89. Agoro, R., et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J. 32 (2018), 3752–3764.
90. Coe, L.M., et al. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J. Biol. Chem. 289 (2014), 9795–9810.
91. Clinkenbeard, E.L., et al. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102 (2017), e427–e430.
92. Shimizu, I., Minamino, T., Physiological and pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 97 (2016), 245–262.
93. Fischer, S.S., et al. Hyperaldosteronism in Klotho-deficient mice. Am. J. Physiol. Renal Physiol. 299 (2010), F1171–F1177.
94. Zhang, B., et al. Up-regulation of FGF23 release by aldosterone. Biochem. Biophys. Res. Commun. 470 (2016), 384–390.
95. Pathare, G., et al. Elevated FGF23 levels in mice lacking the thiazide-sensitive NaCl cotransporter (NCC). Sci. Rep., 8, 2018, 3590.
96. Hanks, L.J., et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One, 10, 2015, e0122885.
97. Hu, X., et al. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes. Sci. Rep., 6, 2016, 34696.
98. Reyes-Garcia, R., et al. FGF23 in type 2 diabetic patients: relationship with bone metabolism and vascular disease. Diabetes Care 37 (2014), e89–e90.
99. Wahl, P., et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 35 (2012), 994–1001.
100. Chan, G.C., et al. FGF23 concentration and APOL1 genotype are novel predictors of mortality in African Americans with type 2 diabetes. Diabetes Care 41 (2018), 178–186.
101. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 (2011), 98–107.
102. Bar, L., et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc. Natl. Acad. Sci. U. S. A. 115 (2018), 5804–5809.
103. Richter, M., et al. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J. Heart Lung Transplant. 34 (2015), 1211–1214.
104. Prie, D., et al. Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list. PLoS One, 8, 2013, e66182.
105. Spichtig, D., et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 85 (2014), 1340–1350.
106. Bansal, S., et al. Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation. Nephrol. Dial. Transplant. 32 (2017), 960–968.
107. Li, D.J., et al. Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism 65 (2016), 747–756.
108. Toro, L., et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 93 (2018), 1131–1141.
109. Kolek, O.I., et al. 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005), G1036–G1042.
110. Saito, H., et al. Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280 (2005), 2543–2549.
111. Sitara, D., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004), 421–432.
112. Morishita, K., et al. The progression of aging in Klotho mutant mice can be modified by dietary phosphorus and zinc. J. Nutr. 131 (2001), 3182–3188.
113. Ohnishi, M., et al. Reversal of mineral ion homeostasis and soft-tissue calcification of Klotho knockout mice by deletion of vitamin D 1α-hydroxylase. Kidney Int. 75 (2009), 1166–1172.
114. Barthel, T.K., et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol. 103 (2007), 381–388.
115. Topaz, O., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36 (2004), 579–581.
116. Rafaelsen, S.H., et al. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J. Bone Miner. Res. 28 (2013), 1378–1385.
117. Yu, X., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 (2005), 4647–4656.